Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | lamin A/C | Starlite/ChEMBL | No references |
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | lamin | 0.0033 | 0.3537 | 1 |
Schistosoma mansoni | lamin | 0.0033 | 0.3537 | 0.6116 |
Brugia malayi | Latrophilin receptor protein 2 | 0.0019 | 0.0375 | 0.0375 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0041 | 0.5545 | 0.5545 |
Schistosoma mansoni | lamin | 0.0033 | 0.3537 | 0.6116 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0033 | 0.3537 | 0.3537 |
Echinococcus granulosus | intermediate filament protein | 0.0033 | 0.3537 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 1 | 1 |
Echinococcus granulosus | lamin dm0 | 0.0033 | 0.3537 | 1 |
Brugia malayi | calcium-independent alpha-latrotoxin receptor 2, putative | 0.0019 | 0.0375 | 0.0375 |
Loa Loa (eye worm) | hypothetical protein | 0.0041 | 0.5545 | 0.5545 |
Brugia malayi | intermediate filament protein | 0.0033 | 0.3537 | 0.3537 |
Schistosoma mansoni | hypothetical protein | 0.0041 | 0.5545 | 1 |
Schistosoma mansoni | intermediate filament proteins | 0.0033 | 0.3537 | 0.6116 |
Onchocerca volvulus | 0.0033 | 0.3537 | 0.5 | |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.006 | 1 | 1 |
Echinococcus multilocularis | musashi | 0.0033 | 0.3537 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0033 | 0.3537 | 0.3537 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0033 | 0.3537 | 0.3537 |
Loa Loa (eye worm) | latrophilin receptor protein 2 | 0.0019 | 0.0375 | 0.0375 |
Loa Loa (eye worm) | hypothetical protein | 0.0019 | 0.0375 | 0.0375 |
Loa Loa (eye worm) | intermediate filament protein | 0.0033 | 0.3537 | 0.3537 |
Onchocerca volvulus | 0.0033 | 0.3537 | 0.5 | |
Echinococcus multilocularis | lamin dm0 | 0.0033 | 0.3537 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0032 | 0.3397 | 0.3397 |
Echinococcus multilocularis | lamin | 0.0033 | 0.3537 | 1 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.006 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 12.5893 um | PUBCHEM_BIOASSAY: qHTS Assay for Modulators of Lamin A Splicing. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 12.5893 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 14.1254 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Agonists. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 22.3872 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Human Jumonji Domain Containing 2E (JMJD2E). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 25.1189 uM | PubChem BioAssay. Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (binding) | = 31.6228 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1). (Class of assay: confirmatory) [Related pubchem assays: 1030 (qHTS Validation Assay for Inhibitors of aldehyde dehydrogenase 1 (ALDH1A1))] | ChEMBL. | No reference |
Potency (binding) | = 44.6684 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 50.1187 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 79.4328 uM | PUBCHEM_BIOASSAY: qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488771] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488771] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PubChem BioAssay. qHTS Assay to Find Inhibitors of Pin1. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.